Morgan Stanley Downgrades Mindray Medical To Underweight

Analysts at Morgan Stanley downgraded Mindray Medical International MR from Equal-weight to Underweight. The price target for Mindray Medical has been lowered from $37 to $28. Mindray Medical shares have declined 24.02% over the past 52 weeks, while the S&P 500 index has gained 14.65% in the same period. Mindray Medical's shares fell 0.28% to close at $28.19 yesterday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: DowngradesAnalyst RatingsMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!